Affirmed Gender Reveals Hidden Metabolic Risks, Suggests Study
A recent study published in the Indian Journal of Endocrinology and Metabolism reveals a dramatic spike in metabolic syndrome diagnoses when transgender individuals are evaluated using their affirmed gender criteria. Strikingly, the identified prevalence nearly doubled, jumping from 31.4% to 63.8% in transgender women and 23.4% to 60% in transgender men.
While irisin is a well-known metabolic marker, its effects during gender-affirming therapy remain poorly understood. To address this gap, Dr. Kamath and her team investigated serum irisin levels and evaluated alternative methods for accurately predicting Metabolic Syndrome in transgender individuals.
Therefore, the researchers conducted a nine-month study of 123 matched transgender and cisgender participants in Bangalore to measure serum irisin and metabolic profiles. By excluding individuals with pre-existing health conditions, the study accurately assessed irisin variations and its ability to predict Metabolic Syndrome during gender-affirming care.
Key Clinical Findings of the Study Includes:
Serum Irisin Disparities: Investigators observed that transgender women exhibited significantly lower median irisin concentrations (11.6 ng/ml) compared to cisgender women (19.7 ng/ml, P = 0.04), whereas the variance between transgender and cisgender men lacked statistical significance.
Cardiovascular Correlations: Analyses revealed an inverse correlation between irisin and diastolic blood pressure in transgender women (r = –0.307, P = 0.036), indicating a potential interaction with cardiovascular health.
Lipid and Hormonal Links: Researchers found that in transgender men, circulating irisin inversely correlated with both high-density lipoprotein cholesterol (r = –0.339) and prolactin levels (r = –0.357).
Diagnostic Index Superiority: Authors demonstrated that irisin possesses limited diagnostic value for MetS (area under the curve < 0.5), whereas alternative measures like the triglyceride-to-high-density lipoprotein ratio proved far more effective for transgender women (AUC = 0.748) and the triglyceride-glucose index for transgender men (AUC = 0.67).
The results suggest that while serum irisin shares targeted associations with select parameters like diastolic blood pressure and prolactin, its predictive capability for MetS is inferior to specialized lipid indices within gender-incongruent cohorts. Specifically, employing affirmed gender metrics alongside the triglyceride-to-high-density lipoprotein or triglyceride-glucose indexes yields a markedly more robust cardiometabolic risk assessment.
Thus, the study concludes healthcare practitioners might benefit from adopting personalized metabolic screening protocols that incorporate specific lipid-based indices rather than relying solely on irisin or birth-assigned gender benchmarks when managing the long-term cardiometabolic health of patients on gender-affirming regimens.
The somewhat restricted sample size and cross-sectional nature of the investigation limit definitive conclusions regarding the long-term physiological impacts of gender-affirming therapies, highlighting a gentle requirement for expanded, longitudinal tracking to more thoroughly comprehend the molecular pathways governing these distinct metabolic shifts.
Reference
Kamath PU, Golamari UR, Nair AS, Kalra P. Evaluation of serum irisin levels in individuals with gender incongruence and its metabolic correlations. Indian J Endocr Metab 2026;30:64‑70.
